Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | STAT1 | P42224 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2794177 | 0.90 | BTK (0.39) | MAPTMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL2531168 | 0.88 | CTSK (0.38) | LMNASTAT1CTSKTP53MAPT | |
| SCHEMBL11791086 | 0.86 | NPC1 (0.36) | LMNASTAT1MAPTALDH1A1RAB9A | |
| SCHEMBL10961090 | 0.84 | SMN1; SMN2 (0.34) | LMNASTAT1CTSKTP53MAPT | |
| SCHEMBL10855247 | 0.84 | CTSK (0.37) | LMNASTAT1CTSKL3MBTL1SMN1; SMN2 | |
| SCHEMBL2535567 | 0.82 | LMNA (0.56) | LMNASTAT1MAPTMEN1KMT2A | |
| SCHEMBL5257151 | 0.80 | TSHR (0.35) | LMNASTAT1TP53MAPTMEN1 | |
| SCHEMBL395325 | 0.76 | DHODH (0.46) | TP53MAPTALDH1A1MAPK1RAB9A | |
| SCHEMBL4147861 | 0.76 | GAA (0.43) | LMNATP53MAPTMEN1KMT2A | |
| SCHEMBL17963282 | 0.75 | CTSK (0.39) | CTSKMEN1KMT2AMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560974-B1 | PYRRAZOLOPYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-01-27 | — | — | EP | disclosed |
| US-8487102-B2 | Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2560974-A1 | PYRRAZOLOPYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011131571-A1 | PYRRAZOLOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-27 | — | — | WO | disclosed |
| US-20110257402-A1 | PYRRAZOLOPYRIDINE COMPOUNDS AS DUAL NK1/NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257402-A1 | PYRRAZOLOPYRIDINE COMPOUNDS AS DUAL NK1/NK3 RECEPTOR ANTAGONISTS | TACR2, GRIN3A, TACR1 | LMNA 4398/4885STAT1 3331/4885CTSK 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.